Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Has Cheapest Drugs Compared To OECD Countries, UK Says

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Australia has the lowest prices for new medicines among developed countries, according to a UK Department of Health report on the Pharmaceutical Price Regulation Scheme

You may also be interested in...



A Closer Look At Australian And New Zealand Drug Reimbursement Programs

Australia's PBS and New Zealand's PHARMAC draw differing responses from industry.

India May Go For Reference Pricing As Negotiated Pricing May Endanger Compulsory License Policy

Reference pricing leaves room for scaling down prices via compulsory licenses.

Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?

A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC074098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel